Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H14N2.2ClH |
| Molecular Weight | 271.186 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.N[C@@H](CC1=CC=CC=N1)C2=CC=CC=C2
InChI
InChIKey=KHJHFYAGQZYCLC-GXKRWWSZSA-N
InChI=1S/C13H14N2.2ClH/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12;;/h1-9,13H,10,14H2;2*1H/t13-;;/m0../s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C13H14N2 |
| Molecular Weight | 198.2637 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25259653/ |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LANICEMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25259653/ |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LANICEMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
16.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25259653/ |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LANICEMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study. | 2001 Feb |
|
| Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block. | 2001 Jun |
|
| NXY-059: a hopeful sign in the treatment of stroke. | 2006 Oct |
Patents
Sample Use Guides
50-150 mg of the drug is given as a single intravenous (iv) infusion over 60 minutes.
Route of Administration:
Intravenous
Rat cortical neurons were exposed to NMDA (50 uM) or glutamate (50 uM) for 15 min, the treatment resulted in the death of 85-95% of the neurons during the next 24 h. Lanicemine inhibited the neurotoxicity at 50 uM, prevented the loss of membrane-associated protein kinase C activity and reduced by approximately 35% the magnitude of NMDA-triggered increases in intracellular free Ca2+ concentration in the cortical cultures.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:28:54 GMT 2023
by
admin
on
Fri Dec 15 16:28:54 GMT 2023
|
| Record UNII |
59E712CNQR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
153322-06-6
Created by
admin on Fri Dec 15 16:28:54 GMT 2023 , Edited by admin on Fri Dec 15 16:28:54 GMT 2023
|
PRIMARY | |||
|
59E712CNQR
Created by
admin on Fri Dec 15 16:28:54 GMT 2023 , Edited by admin on Fri Dec 15 16:28:54 GMT 2023
|
PRIMARY | |||
|
9795446
Created by
admin on Fri Dec 15 16:28:54 GMT 2023 , Edited by admin on Fri Dec 15 16:28:54 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |